AXS Investments LLC Invests $183,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AXS Investments LLC purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,490 shares of the specialty pharmaceutical company’s stock, valued at approximately $183,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Polaris Capital Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 2.2% in the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after buying an additional 27,100 shares during the period. International Assets Investment Management LLC purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $7,201,000. Desjardins Global Asset Management Inc. purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $1,943,000. Kovack Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 347.1% during the 4th quarter. Kovack Advisors Inc. now owns 29,971 shares of the specialty pharmaceutical company’s stock worth $3,686,000 after acquiring an additional 23,267 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Jazz Pharmaceuticals by 94.2% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock valued at $11,210,000 after purchasing an additional 44,414 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the transaction, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Stock Up 2.0 %

NASDAQ JAZZ traded up $2.12 during trading on Friday, hitting $106.06. The company’s stock had a trading volume of 675,815 shares, compared to its average volume of 705,416. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70. The company has a market cap of $6.69 billion, a PE ratio of 21.87, a P/E/G ratio of 1.62 and a beta of 0.63. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. The business’s 50 day simple moving average is $113.06 and its 200-day simple moving average is $118.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The company had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and issued a $222.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 2nd. StockNews.com lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Truist Financial reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Stifel Nicolaus boosted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Piper Sandler raised their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $192.75.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.